Information to authors
Mahdian Expression Profile of MiR200 Family Members and Their Targets in Prostate Cancer
Prostate cancer (PCa) shows the highest rate of new cancer cases in male population. Low sensitivity and specificity of traditional diagnostic tests have limited their implementation for early detection of PCa. The differential expression pattern of miR200 family and their target genes has the potential of being considered as biomarkers for prostate cancer detection in combination with traditional screening. In this study we aimed to investigate changes in the expression profiles of the miR200 family members/targets in PCa tissue samples. We examined the miR200 family members and their target genes (TCF7L1, CTBP2, E2F3, CTNNB1, DLC1 and EP300) expression profile using quantitative Realtime PCR (samples n = 24). The results showed decreased mean expression level of miR200a and miR429 and DLC1 gene in tumor samples. Also, the expression level of E2F3, CTNNB1, EP300, CTBP2 and TCF7L1 genes was upregulated in the tumor samples. ROC and AUC analysis showed that the combination of miR200 family and their target genes expression profile successfully discriminated PCa samples from their nontumor counterparts (miR200 family AUC = 0.699, p < 0.01 and target genes AUC = 0.899, p < 0.0001, respectively). The results of this study indicate that the deregulated expression of the miR200 family and their gene targets may have a role in the pathogenesis of PCa. We suggest further assessment of the expression profile of miR200 family and their target genes in comparison with other PCa diagnostic biomarkers.
Key words: Biomarker, MicroRNAs, miR200 family, Prostate cancer, Quantitative Realtime PCR
E-mail: dr.reza.mahdian gmail.com
1. Ahmad, J., Hasnain, S.E., Siddiqui, M.A., Ahamed, M., Musarrat, J., and Al-Khedhairy, A.A., MicroRNA in carcinogenesis and cancer diagnostics: a new paradigm, Indian J. Med. Res., 2013, vol.137, no. 4, p. 680.
2. Alhasan, A.H., Scott, A.W., Wu, J.J., Feng, G., Meeks, J.J., Thaxton, C.S., and Mirkin, C.A., Circulating microRNA signature for the diagnosis of very high-risk prostate cancer, Proc. Natl. Acad. Sci. U. S. A., 2016, vol. 113, no. 38, pp. 10655–10660.
3. Ambs, S., Prueitt, R.L., Yi, M., Hudson, R.S., Howe, T.M., Petrocca, F., Wallace, T.A., Liu, C.-G., Volinia, S., and Calin, G.A., Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer, Cancer Res., 2008, vol. 68, no. 15, pp. 6162–6170.
4. Anastas, J.N. and Moon, R.T., WNT signalling pathways as therapeutic targets in cancer, Nat. Rev. Cancer, 2013, vol. 13, no. 1, p. 11.
5. Arunkumar, G., Rao, D.M., Kuha, A., Manikandan, M., Prasanna Srinivasa Rao, H., Subbiah, S., Ilangovan, R., Murugan, A.K., and Munirajan, A.K., Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma, Oncol. Lett., 2018, vol. 15, no. 1, pp. 649–657.
6. Braun, J., Hoang-Vu, C., Dralle, H., and Huttelmaier, S., Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas, Oncogene, 2010, vol. 29, no. 29, pp. 4237–4244.
7. Carter, J.V., Pan, J., Rai, S.N., and Galandiuk, S., ROC-ing along: evaluation and interpretation of receiver operating characteristic curves, Surgery, 2016, vol. 159, no. 6, pp. 1638–1645.
8. Cary, K.C. and Cooperberg, M.R., Biomarkers in prostate cancer surveillance and screening: past, present, and future, Ther. Adv. Urol., 2013, vol. 5, no. 6, pp. 318–329.
9. da Silva, H.B., Amaral, E.P., Nolasco, E.L., de Victo, N.C., Atique, R., Jank, C.C., Anschau, V., Zerbini, L.F., and Correa, R.G., Dissecting major signaling pathways throughout the development of prostate cancer, Prostate Cancer, 2013.
10. Feng, X., Wang, Z., Fillmore, R., and Xi, Y., MiR-200, a new star miRNA in human cancer, Cancer Lett., 2014, vol. 344, no. 2, pp. 166–173.
11. Filella, X. and Foj, L., miRNAs as novel biomarkers in the management of prostate cancer, Clin. Chem. Lab. Med., 2017, vol. 55, no. 5, pp. 715–736. https://doi.org/10.1515/cclm-2015-1073
12. Foster, C.S., Falconer, A., Dodson, A.R., Norman, A.R., Dennis, N., Fletcher, A., Southgate, C., Dowe, A., Dearnaley, D., and Jhavar, S., Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome, Oncogene, 2004, vol. 23, no. 35, pp. 5871–5879.
13. Ghahhari, N.M. and Babashah, S., Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial–mesenchymal transition in cancer, Eur. J. Cancer, 2015, vol. 51, no. 12, pp. 1638–1649.
14. Groskopf, J., Aubin, S.M., Deras, I.L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., and Meyer, T., APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer, Clin. Chem., 2006, vol. 52, no. 6, pp. 1089–1095.
15. Guan, M., Zhou, X., Soulitzis, N., Spandidos, D.A., and Popescu, N.C., Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications, Clin. Cancer Res., 2006, vol. 12, no. 5, pp. 1412–1419.
16. Haldrup, C., Kosaka, N., Ochiya, T., Borre, M., Hoyer, S., Orntoft, T.F., and Sorensen, K.D., Profiling of circulating microRNAs for prostate cancer biomarker discovery, Drug Deliv. Transl. Res., 2014, vol. 4, no. 1, pp. 19–30.
17. Humphries, B. and Yang, C., The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy, Oncotarget, 2015, vol. 6, no. 9, p. 6472.
18. Jaiswal, S., Sarmad, R., Arora, S., Dasaraju, R., and Sarmad, K., Prostate cancer for the internist, N. Am. J. Med. Sci., 2015, vol. 7, no. 10, p. 429.
19. Khorasani, M., Teimoori-Toolabi, L., Farivar, T.N., Asgari, M., Abolhasani, M., Shahrokh, H., Afgar, A., Kalantari, E., Peymani, A., and Mahdian, R., Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer, Cancer Biomark, 2018, vol. 22, no. 1, pp. 19–28. https://doi.org/10.3233/cbm-170696
20. Koutsaki, M., Libra, M., Spandidos, D.A., and Zaravinos, A., The miR-200 family in ovarian cancer, Oncotarget, 2017, vol. 8, no. 39, p. 66629.
21. Leone, G., DeGregori, J., Yan, Z., Jakoi, L., Ishida, S., Williams, R.S., and Nevins, J.R., E2F3 activity is regulated during the cell cycle and is required for the induction of S phase, Genes Dev., 1998, vol. 12, no. 14, pp. 2120–2130.
22. Maierthaler, M., Benner, A., Hoffmeister, M., Surowy, H., Jansen, L., Knebel, P., Chang-Claude, J., Brenner, H., and Burwinkel, B., Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer, Int. J. Cancer, 2017, vol. 140, no. 1, pp. 176–187.
23. McDermott, J.E., Wang, J., Mitchell, H., Webb-Robertson, B.-J., Hafen, R., Ramey, J., and Rodland, K.D., Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics data, Expert Opin. Med. Diagn., 2013, vol. 7, no. 1, pp. 37–51.
24. Murata, T., Takayama, K., Katayama, S., Urano, T., Horie-Inoue, K., Ikeda, K., Takahashi, S., Kawazu, C., Hasegawa, A., and Ouchi, Y., miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression, Prostate Cancer Prostat. Dis., 2010, vol. 13, no. 4, p. 356.
25. Nakazawa, M. and Kyprianou, N., Epithelial-mesenchymal-transition regulators in prostate cancer: androgens and beyond, J. Steroid Biochem. Mol. Biol., 2017, vol. 166, pp. 84–90.
26. Ozen, M., Creighton, C., Ozdemir, M., and Ittmann, M., Widespread deregulation of microRNA expression in human prostate cancer, Oncogene, 2008, vol. 27, no. 12, p. 1788.
27. Pendlebury, A., Hannan, N.J., Binder, N., Beard, S., Mcgauran, M., Grant, P., Tong, S., and Whitehead, C.L., The circulating microRNA-200 family in whole blood are potential biomarkers for high-grade serous epithelial ovarian cancer, Biomed. Rep., 2017, vol. 6, no. 3, pp. 319–322.
28. Rice, K.R., Chen, Y., Ali, A., Whitman, E.J., Blase, A., Ibrahim, M., Elsamanoudi, S., Brassell, S., Furusato, B., and Stingle, N., Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer, Clin. Cancer Res., 2010, pp. 1078–0432. CCR-1009-2191.
29. Saini, S., PSA and beyond: alternative prostate cancer biomarkers, Cell. Oncol., 2016, vol. 39, no. 2, pp. 97–106.
30. Schaefer, A., Jung, M., Miller, K., Lein, M., Kristiansen, G., Erbersdobler, A., and Jung, K., Suitable reference genes for relative quantification of miRNA expression in prostate cancer, Exp. Mol. Med., 2010, vol. 42, no. 11, pp. 749–758.
31. Shahbazi, S., Khorasani, M., and Mahdian, R., Gene expression profile of FVII and AR in primary prostate cancer, Cancer Biomarkers, 2016, vol. 17 (3):353-358.
32. Siegel, R.L., Miller, K.D., and Jemal, A., Cancer Statistics, 2017, CA Cancer J. Clin., 2017, vol. 67, no. 1, pp. 7–30. https://doi.org/10.3322/caac.21387
33. Szczyrba, J., Löprich, E., Wach, S., Jung, V., Unteregger, G., Barth, S., Grobholz, R., Wieland, W., Stöhr, R., and Hartmann, A., The microRNA profile of prostate carcinoma obtained by deep sequencing, Mol. Cancer Res., 2010, pp. 1541–7786. MCR-1509-0443.
34. Tripathi, V., Popescu, N.C., and Zimonjic, D.B., DLC1 suppresses NF-kB activity in prostate cancer cells due to its stabilizing effect on adherens junctions, SpringerPlus, 2014, vol. 3, no. 1, p. 27.
35. Watahiki, A., Macfarlane, R.J., Gleave, M.E., Crea, F., Wang, Y., Helgason, C.D., and Chi, K.N., Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer, Int. J. Mol. Sci., 2013, vol. 14, no. 4, pp. 7757–7770.
36. Wei, J., Gao, W., Zhu, C.-J., Liu, Y.-Q., Mei, Z., Cheng, T., and Shu, Y.-Q., Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer, Chin. J. Cancer, 2011, vol. 30, no. 6, p. 407.
37. Wiklund, E.D., Bramsen, J.B., Hulf, T., Dyrskjot, L., Ramanathan, R., Hansen, T.B., Villadsen, S.B., Gao, S., Ostenfeld, M.S., and Borre, M., Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer, Int. J. Cancer, 2011, vol. 128, no. 6, pp. 1327–1334.
38. Williams, L.V., Veliceasa, D., Vinokour, E., and Volpert, O.V., miR-200b inhibits prostate cancer EMT, growth and metastasis, PLoS One, 2013, vol. 8, no. 12, e83991.
39. Xu, G., Wu, J., Zhou, L., Chen, B., Sun, Z., Zhao, F., and Tao, Z., Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing, PLoS One, 2010, vol. 5, no. 11, e15519.
40. Yam, J.W.P., Tse, E.Y.T., and Ng, I.O.L., Role and significance of focal adhesion proteins in hepatocellular carcinoma, J. Gastroenterol. Hepatol., 2009, vol. 24, no. 4, pp. 520–530.
41. Zhu, W., He, J., Chen, D., Zhang, B., Xu, L., Ma, H., Liu, X., Zhang, Y., and Le, H., Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer, PLoS One, 2014, vol. 9, no. 2, e87780.
42. Zidar, N., Boštjančič, E., Gale, N., Kojc, N., Poljak, M., Glavač, D., and Cardesa, A., Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck—hallmark of epithelial-mesenchymal transition, Hum. Pathol., 2011, vol. 42, no. 4, pp. 482–488.
|Coded & Designed by Volodymyr Duplij||Modified 03.10.23|